Markets

Cystic fibrosis biotech ProQR Therapeutics files for a $75 million IPO

ProQR Therapeutics, a dutch biotech developing mRNA treatments for cystic fibrosis, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.

The Leiden, Netherlands-based company, which was founded in 2012, plans to list on the NASDAQ but has not selected a ticker. ProQR Therapeutics initially filed confidentially on July 11, 2014. Leerink Partners and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More